Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

NCT03577743 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT03577743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03577743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
Lead sponsor
Assiut University
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2018
Completion date
February 15, 2021
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, metastatic triple negative breast cancer, safety issues